Search Results
Mar 12, 2026, 10:27 ET Klotho Neurosciences Completes Rebranding to Greenland Mines Ltd and Change of Nasdaq Ticker Symbol to GRML
of the Skaergaard Project in Southeast Greenland, one of the largest undeveloped palladium, gold, and platinum deposits in the world; and 2) Cell and Gene Therapy, including Klotho's KLTO-202 primary indication for ALS. The Company holds, through its recent acquisition of Greenland Mines Corp., an 80%
More news about: Klotho Neurosciences, Inc.
Mar 12, 2026, 10:02 ET Stämm Redefines Biomanufacturing With a Bubble-Free, High-Throughput Bioprocessor Built for Decentralized Production
infrastructure constraints that slow research and development, and future versions aim to accelerate the development process of biologics and cell & gene therapies. Easy to use and designed for deployment anywhere in the world, the HTB targets the widening gap between biological discovery and the scalable
More news about: Stämm
Mar 12, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines - RGNX
2026, Regenxbio issued a press release "announc[ing] that the U.S. Food and Drug Administration (FDA) placed a clinical hold on its investigational gene therapy, RGX-111, for the treatment of MPS I, also known as Hurler syndrome, following preliminary analysis of a single case of neoplasm (intraventricular
More news about: Pomerantz LLP
Mar 12, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in uniQure N.V. of Class Action Lawsuit and Upcoming Deadlines - QURE
from the U.S. Food and Drug Administration (FDA) during a recent pre-Biologics License Application (BLA) meeting regarding AMT-130, an investigational gene therapy for Huntington's disease (HD)." The press release stated that, "based on the discussions at the meeting, uniQure believes that the FDA currently
More news about: Pomerantz LLP
Mar 12, 2026, 09:05 ET BioMarin Presents New Data on the Positive Impact of Early Treatment With VOXZOGO® (vosoritide) on Proportionality and Arm Span in Children with Achondroplasia at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting
This condition is caused by a change in the FGFR3 gene, a negative regulator of bone growth.More than 80% of children with achondroplasia have parents of average stature and have the condition as the result of a spontaneous gene mutation. The worldwide incidence rate of achondroplasia is
More news about: BioMarin Pharmaceutical Inc.
Mar 12, 2026, 09:00 ET Kenai Therapeutics Appoints Allen Waldrop to Board of Directors
funding from the California Institute for Regenerative Medicine (CIRM), a state of California Agency that funds regenerative medicine, stem cell, and gene therapy research. (Grant Numbers CLIN1-14300; CLIN2-19068).About Kenai TherapeuticsKenai Therapeutics is a clinical-stage biotechnology
More news about: Kenai Therapeutics/BIOCOM
Mar 12, 2026, 09:00 ET STEPHEN PAKOLA OVERSAW RGX-111 SAFETY CLAIMS THAT COST RGNX INVESTORS MILLIONS: SUEWALLST
Medical Officer, is named as an individual defendant in a securities class action alleging that his repeated public assurances about the safety of RGX-111 gene therapy concealed material risks from investors. When the truth emerged on January 28, 2026, RGNX shares fell $2.40 per share, a decline of 17.8%, closing
More news about: SueWallSt.com
Mar 12, 2026, 08:53 ET CityUHK researchers unveil the mystery of "Asian Flush" mechanism, pioneering new directions in precision treatment for heart attacks
leading to a rapid deterioration of cardiac tissue. This discovery opens new doors for precision prevention and treatment for hundreds of millions of gene carriers worldwide.The study highlights that the ALDH2 mutation does not only impair alcohol metabolism but also significantly worsens heart
More news about: City University of Hong Kong (CityUHK)
Mar 12, 2026, 08:33 ET CityUHK researchers unveil the mystery of "Asian Flush" mechanism, pioneering new directions in precision treatment for heart attacks
leading to a rapid deterioration of cardiac tissue. This discovery opens new doors for precision prevention and treatment for hundreds of millions of gene carriers worldwide.The study highlights that the ALDH2 mutation does not only impair alcohol metabolism but also significantly worsens heart
More news about: City University of Hong Kong (CityUHK)
Mar 12, 2026, 08:00 ET MyOme Debuts Zenith™ Portfolio with Natera and Launches Long-Read Methylation Analysis at ACMG 2026
platform. This added capability allows clinicians to (1) resolve variants of uncertain significance when a methylation signature is available for a gene and (2) assist in resolving imprinting conditions when parental samples are missing. "It is increasingly clear that the next frontier in addressing
More news about: MyOme, Inc
Mar 12, 2026, 08:00 ET Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference
DystrophyDuchenne Muscular Dystrophy is a rare, progressive, neuromuscular disorder caused by one or more mutations in the dystrophin gene. Symptoms typically emerge in early childhood and include progressive muscle weakness, loss of ambulation, respiratory compromise, and cardiomyopathy.
More news about: Atossa Therapeutics Inc
Mar 12, 2026, 03:01 ET GenScript Strengthens Transatlantic Biotech Infrastructure with European mRNA Hub
one of Europe's strongest life science ecosystems, the Delft site provides end-to-end mRNA workflow capabilities, including:Gene design and synthesisVector engineeringIVT mRNA productionProprietary GenCap™ mRNA capping technologyUTR optimization
More news about: GenScript Biotech Corporation
Mar 12, 2026, 02:49 ET GenScript Strengthens Transatlantic Biotech Infrastructure with European mRNA Hub
one of Europe's strongest life science ecosystems, the Delft site provides end-to-end mRNA workflow capabilities, including:Gene design and synthesisVector engineeringIVT mRNA productionProprietary GenCap™ mRNA capping technologyUTR optimization
More news about: GenScript Biotech Corporation
Mar 11, 2026, 19:41 ET Locus Cell, Taiwan-Based Cell and Gene Therapy CDMO, Signs MoU with Charles River at APAC Biomanufacturing Leadership Summit
SINGAPORE, March 11, 2026 /PRNewswire/ -- Locus Cell Co., Ltd. ("Locus Cell"), a Taiwan-based cell and gene therapy (CGT) Contract Development and Manufacturing Organization (CDMO), and Charles River Laboratories ("Charles River"), a global contract research
More news about: Locus Cell Co., Ltd.
Mar 11, 2026, 13:33 ET Bota lança SAION AI, a plataforma física de IA para biomanufatura
públicos. Combinado com os principais modelos AI4Science, o SAION AI desenvolve uma compreensão em múltiplas escalas em todo o continuum gene-proteína-célula-fermentação, permitindo um design sistemático e decisões científicas baseadas em dados.Orquestração: coordenação de pesquisa inteligenteA
More news about: Bota
Mar 11, 2026, 12:23 ET Full Circles Therapeutics Highlights Circular Single-Stranded DNA Platform Enabling Immune-Evasive Genome Writing in Nature Study
fibrosis and ß-thalassemia, are caused by hundreds of distinct mutations within the same gene across patient populations. A gene replacement strategy enabled by C4DNA could instead insert a healthy copy of an entire gene, such as CFTR or HBB, into a defined genomic location, providing a mutation-agnostic
More news about: Full Circles Therapeutics
Mar 11, 2026, 11:45 ET REGENXBIO REPORTS NEW POSITIVE INTERIM DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202
BLA submission.About RGX-202RGX-202 is a potential best-in-class investigational gene therapy designed for improved function and outcomes in Duchenne. RGX-202 is the only gene therapy approved or in late-stage development for Duchenne with a differentiated microdystrophin construct
More news about: REGENXBIO Inc.
Mar 11, 2026, 10:34 ET Bota lance SAION AI - Plateforme d'IA physique pour la biofabrication
données biologiques publiques. Combinée aux principaux modèles AI4Science, SAION AI développe une compréhension multi-échelle du continuum gène-protéine-cellule-fermentation, permettant une conception systématique et des décisions scientifiques basées sur les données.Orchestration : coordination intelligente
More news about: Bota
Mar 11, 2026, 09:36 ET RGNX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026
2026, REGENXBIO issued a press release "announc[ing] that the U.S. Food and Drug Administration (FDA) placed a clinical hold on its investigational gene therapy, RGX-111, for the treatment of MPS I, also known as Hurler syndrome, following preliminary analysis of a single case of neoplasm (intraventricular
More news about: Faruqi & Faruqi, LLP
Mar 11, 2026, 09:03 ET Bota ra mắt SAION AI -- Nền tảng AI Vật lý cho sản xuất sinh học
liệu sinh học công khai. Kết hợp với các mô hình AI4Science hàng đầu, SAION AI phát triển khả năng hiểu biết đa quy mô trên toàn bộ chuỗi liên kết gene – protein – tế bào – lên men, cho phép thiết kế có hệ thống và đưa ra các quyết định khoa học dựa trên dữ liệu.Điều phối: Điều phối nghiên cứu
More news about: Bota
Mar 11, 2026, 09:00 ET Investors who lost money on REGENXBIO Inc.(RGNX) should contact Levi & Korsinsky about pending Class Action - RGNX
defendants provided investors with material information concerning REGENXBIO's plan to develop and commercialize its product candidate RGX-111, a one-time gene therapy for the treatment of severe Mucopolysaccharidosis Type I, also known as Hurler syndrome. Defendants' statements included, among other things,
More news about: Levi & Korsinsky, LLP
Mar 11, 2026, 09:00 ET STEPHEN PAKOLA OVERSAW RGX-111 SAFETY CLAIMS THAT COST RGNX INVESTORS MILLIONS: LEVI & KORSINSKY, LLP
Medical Officer, is named as an individual defendant in a securities class action alleging that his repeated public assurances about the safety of RGX-111 gene therapy concealed material risks from investors. When the truth emerged on January 28, 2026, RGNX shares fell $2.40 per share, a decline of 17.8%, closing
More news about: Levi & Korsinsky, LLP
Mar 11, 2026, 08:30 ET Caris Life Sciences to Showcase Five Studies at the 2026 USCAP Annual Meeting
2:00 PM – 2:15 PM CDTPosters Include:Landscape and Molecular/Clinical Correlates of Pathogenic Gene Fusions in Melanoma: A Comprehensive Molecular Profiling Study. Poster #48Poster II - Monday PM - Dermatopathology. March 23,
More news about: Caris Life Sciences
Mar 11, 2026, 04:00 ET ARTHEx Biotech Granted FDA Fast Track Designation for ATX-01 for the Treatment of Myotonic Dystrophy Type 1 (DM1)
information.About ARTHEx BiotechARTHEx Biotech is a clinical-stage company developing targeted RNA medicines designed to precisely modulate gene expression. Its proprietary platform, BOOST-ON™, pairs selective oligonucleotides with enhanced tissue delivery to reach skeletal muscle, heart, and
More news about: ARTHEx Biotech
Mar 10, 2026, 18:08 ET Bota Launches SAION AI -- Physical AI Platform for Biomanufacturing
publications and patents, and public biological databases. Combined with leading AI4Science models, SAION AI develops multi-scale understanding across the gene–protein–cell–fermentation continuum, enabling systematic design and data-driven scientific decisions.Orchestration: Intelligent Research CoordinationThe
More news about: Bota